Boston, MA 10/04/2013 (wallstreetpr) – Shareholders at Pfizer Inc. (NYSE:PFE) have seen an increase in the value of their shares by up to 11% this year alone a clear indication of the company’s steady growth in its core holding portfolios. Pfizer has been doing exemplary well in the market with its stock rising high by up to 60% in the past two years making it the best caped drug manufacturer in the past 5 years.
Pfizer has continued to attract investor’s year in year out through its efforts of spending huge amount of capital on research and development. This way it has acquired profitable patents that have allowed it to acquire and maintain a constant stream of royalties. Pfizer resent revelations that it had received FDA approval for DUAVEETM 0.45MG/20MG looks set to have a positive impact on the company’s stock. The drug has been tested and found to be ideal in treating of severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis. The drug is expected to be available in the first quarter of next year.
Pfizer has engaged itself in strategies of constantly developing and launching new drugs in the market to boost its revenue. The drug development of DUAVEETM is part of Pfizer collaboration with Ligand pharmaceuticals. After the announcement of the approval of the drug, Pfizer shares were up by 4% at $49.89 indicating its shares could do good in future with this kind of. The only drawback that is making Pfizer not reach its potential is the constant risk it faces in foreign currency transactions. In Q2 revenues were impacted by foreign currency transaction of up to $400million while the costs of sales declined by $146million .Pfizer has purchased back shares totaling $8.7 billion in 2013 alone and has been noted as having consistent record of always increasing its dividends.
